Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance
Journal of Biochemical and Molecular Toxicology · 2026-08 · 40 (8)
DOI: 10.1002/jbt.71035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 25.07.2026. Verfasst von Shuilan Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drug Resistance, Neoplasm, Lactic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 178 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovation and entrepreneurship training program for college students of Guangxi Medical University, Guangxi Zhuang Autonomous Region Health Committee self-funded scientific research.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a highly lethal malignancy worldwide. Lactylation, which serves as a key metabolic‐epigenetic bridge driving malignant progression, is involved in CRC development, metastasis, immunosuppression, and drug resistance. This review systematically outlines the biological functions of lactate and the molecular mechanisms of lactylation, with a particular focus on their regulatory roles in CRC. Key aspects are summarized, including the dynamic regulation by lactylation‐related enzymes (“writers” and “erasers”) and potential therapeutic strategies targeting lactylation. Distinct from existing studies, this review further explores the clinical translational potential of targeting lactylation. From a toxicological perspective, it analyzes mechanisms of chemotherapy resistance and the toxicological considerations associated with targeted therapies. Core challenges in clinical translation, such as off‐target toxicity, optimization of the therapeutic index, and low drug delivery efficiency—are also examined. By synthesizing the latest research advances in lactylation modification in CRC, this review provides a clear framework to inform and guide subsequent basic research and clinical translation efforts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College of Guangxi Medical University, Nanning, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
- Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Nanning, China.
ORCID-Profile: Qisheng Su, Xiaohong Li
Förderung
- Innovation and entrepreneurship training program for college students of Guangxi Medical University
- Guangxi Zhuang Autonomous Region Health Committee self-funded scientific research
Zitieren
APA
Yao, S., Liang, Y., Liang, X., Su, Q., & Li, X. (2026). Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance. Journal of Biochemical and Molecular Toxicology, 40(8). https://doi.org/10.1002/jbt.71035
Vancouver
Yao S, Liang Y, Liang X, Su Q, Li X. Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance. Journal of Biochemical and Molecular Toxicology. 2026;40(8). doi:10.1002/jbt.71035
BibTeX
@article{Yao2026,
author = {Yao, Shuilan and Liang, Yun and Liang, Xinwen and Su, Qisheng and Li, Xiaohong},
title = {Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {8},
doi = {10.1002/jbt.71035}
}
EUVIMED